AlzChem CEO Niedermaier reviews H1 2026 performance in Boersenradio interview
Sphene Capital lifts AlzChem price target to EUR 204.5, keeps buy rating
Montega reiterates Buy on AlzChem, sets EUR 220 price target
ACT: Strong H1 2026 growth driven by Specialty Chemicals, with guidance confirmed and expansions on track
AlzChem: Buy Rating Reiterated as Solid Operations and Capacity Expansions Support FY26 Outlook; Price Target Maintained at $200
ACT: Specialty Chemicals drove double-digit profit growth in H1 2026, with robust outlook confirmed